JP2014509653A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014509653A5 JP2014509653A5 JP2014502821A JP2014502821A JP2014509653A5 JP 2014509653 A5 JP2014509653 A5 JP 2014509653A5 JP 2014502821 A JP2014502821 A JP 2014502821A JP 2014502821 A JP2014502821 A JP 2014502821A JP 2014509653 A5 JP2014509653 A5 JP 2014509653A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- treatment
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 claims 20
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 150000001875 compounds Chemical class 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 5
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 claims 5
- 102000003964 Histone deacetylases Human genes 0.000 claims 4
- 108090000353 Histone deacetylases Proteins 0.000 claims 4
- 239000004480 active ingredient Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 4
- 230000001404 mediated Effects 0.000 claims 4
- 230000002062 proliferating Effects 0.000 claims 4
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010017758 Gastric cancer Diseases 0.000 claims 2
- 206010073071 Hepatocellular carcinoma Diseases 0.000 claims 2
- 206010020243 Hodgkin's disease Diseases 0.000 claims 2
- 208000007766 Kaposi Sarcoma Diseases 0.000 claims 2
- 206010024324 Leukaemias Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 206010025650 Malignant melanoma Diseases 0.000 claims 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 2
- 206010025310 Other lymphomas Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- 208000003154 Papilloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 206010041823 Squamous cell carcinoma Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 201000011231 colorectal cancer Diseases 0.000 claims 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 1
Claims (20)
- 式I：
(式中、Rは水素またはアシル基である)
の化合物またはその薬学的に許容され得る塩。 - RがR1C(O)-であり、ここでR1が、置換もしくは非置換C1-C24アルキル；置換もしくは非置換C2-C24アルケニル；置換もしくは非置換C2-C24アルキニル；置換もしくは非置換アリール；または置換もしくは非置換ヘテロアリールである、請求項１記載の化合物。
- RがHまたはアセチルである、請求項１記載の化合物。
- 式：
で表される請求項１記載の化合物またはその薬学的に許容され得る塩。 - 有効成分として請求項１記載の化合物、および薬学的に許容され得る担体を含む、医薬組成物。
- 有効成分として請求項１記載の化合物、および薬学的に許容され得る担体を含む、経口投与用の医薬組成物。
- 有効成分として請求項４記載の化合物、および薬学的に許容され得る担体を含む、医薬組成物。
- 有効成分として請求項４記載の化合物、および薬学的に許容され得る担体を含む、経口投与用の医薬組成物。
- PI3Kに関連する疾患または障害の治療を必要とする被験体における、PI3Kに関連する疾患または障害の治療のための、請求項５記載の医薬組成物。
- 前記PI3Kに関連する疾患または障害が、細胞増殖性障害である、請求項９記載の医薬組成物。
- 細胞増殖性障害が癌である、請求項１０記載の医薬組成物。
- 癌が、乳頭腫、ブラストグリオーマ(blastoglioma)、カポジ肉腫、メラノーマ、非小細胞肺癌、卵巣癌、前立腺癌、扁平上皮癌、星状細胞腫、頭部癌、頚部癌、膀胱癌、乳癌、肺癌、結腸直腸癌、甲状腺癌、膵臓癌、胃癌、肝細胞癌、白血病、リンパ腫、ホジキン病およびバーキット病からなる群より選択される、請求項１１記載の医薬組成物。
- HDAC媒介性疾患の治療のための、請求項５記載の医薬組成物。
- PI3KおよびHDACの両方によって媒介される疾患の治療のための、請求項５記載の医薬組成物。
- PI3Kに関連する疾患または障害の治療のための、請求項７記載の医薬組成物。
- 前記PI3Kに関連する疾患または障害が、細胞増殖性障害である、請求項１５記載の医薬組成物。
- 細胞増殖性障害が癌である、請求項１６記載の医薬組成物。
- 癌が、乳頭腫、ブラストグリオーマ(blastoglioma)、カポジ肉腫、メラノーマ、非小細胞肺癌、卵巣癌、前立腺癌、扁平上皮癌、星状細胞腫、頭部癌、頚部癌、膀胱癌、乳癌、肺癌、結腸直腸癌、甲状腺癌、膵臓癌、胃癌、肝細胞癌、白血病、リンパ腫、ホジキン病およびバーキット病からなる群より選択される、請求項１７記載の医薬組成物。
- HDAC媒介性疾患の治療のための、請求項７記載の医薬組成物。
- PI3KおよびHDACの両方によって媒介される疾患の治療のための、請求項７記載の医薬組成物。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161470849P | 2011-04-01 | 2011-04-01 | |
| US61/470,849 | 2011-04-01 | ||
| US201161559489P | 2011-11-14 | 2011-11-14 | |
| US61/559,489 | 2011-11-14 | ||
| PCT/US2012/031361 WO2012135571A1 (en) | 2011-04-01 | 2012-03-30 | Phosphoinositide 3-kinase inhibitor with a zinc binding moiety |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016155625A Division JP6275784B2 (ja) | 2011-04-01 | 2016-08-08 | 亜鉛結合部分を有するホスホイノシチド３−キナーゼインヒビター |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014509653A JP2014509653A (ja) | 2014-04-21 |
| JP2014509653A5 true JP2014509653A5 (ja) | 2015-04-09 |
| JP6242331B2 JP6242331B2 (ja) | 2017-12-06 |
Family
ID=46931927
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014502821A Active JP6242331B2 (ja) | 2011-04-01 | 2012-03-30 | 亜鉛結合部分を有するホスホイノシチド３−キナーゼインヒビター |
| JP2016155625A Active JP6275784B2 (ja) | 2011-04-01 | 2016-08-08 | 亜鉛結合部分を有するホスホイノシチド３−キナーゼインヒビター |
| JP2018001910A Withdrawn JP2018052987A (ja) | 2011-04-01 | 2018-01-10 | 亜鉛結合部分を有するホスホイノシチド３−キナーゼインヒビター |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016155625A Active JP6275784B2 (ja) | 2011-04-01 | 2016-08-08 | 亜鉛結合部分を有するホスホイノシチド３−キナーゼインヒビター |
| JP2018001910A Withdrawn JP2018052987A (ja) | 2011-04-01 | 2018-01-10 | 亜鉛結合部分を有するホスホイノシチド３−キナーゼインヒビター |
Country Status (30)
| Country | Link |
|---|---|
| US (7) | US8710219B2 (ja) |
| EP (2) | EP2694075B1 (ja) |
| JP (3) | JP6242331B2 (ja) |
| KR (2) | KR101902325B1 (ja) |
| CN (2) | CN103582483B (ja) |
| AU (1) | AU2012236367B2 (ja) |
| BR (1) | BR112013025340B1 (ja) |
| CA (1) | CA2830822C (ja) |
| CL (1) | CL2013002823A1 (ja) |
| CY (2) | CY1117785T1 (ja) |
| DK (2) | DK3111938T3 (ja) |
| EA (1) | EA022434B9 (ja) |
| ES (2) | ES2733128T3 (ja) |
| HK (1) | HK1194969A1 (ja) |
| HR (2) | HRP20160545T1 (ja) |
| HU (2) | HUE045041T2 (ja) |
| IL (2) | IL228588A (ja) |
| LT (1) | LT3111938T (ja) |
| ME (2) | ME03523B (ja) |
| MX (1) | MX340577B (ja) |
| PE (1) | PE20141382A1 (ja) |
| PL (2) | PL2694075T3 (ja) |
| PT (2) | PT3111938T (ja) |
| RS (2) | RS54903B1 (ja) |
| SG (2) | SG10201602569RA (ja) |
| SI (2) | SI3111938T1 (ja) |
| SM (1) | SMT201600179B (ja) |
| TW (1) | TWI571469B (ja) |
| WO (1) | WO2012135571A1 (ja) |
| ZA (2) | ZA201307082B (ja) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101430424B1 (ko) | 2009-01-08 | 2014-08-14 | 쿠리스 인코퍼레이션 | 아연 결합 모이어티를 갖는 포스포이노시티드 ３-키나제 억제제 |
| RS54903B1 (sr) * | 2011-04-01 | 2016-10-31 | Curis Inc | Inhibitor fosfoinozitid 3 kinaze sa delom koji vezuje cink |
| AU2012339640B2 (en) | 2011-11-14 | 2017-01-05 | Ignyta, Inc. | Uracil derivatives as AXL and c-MET kinase inhibitors |
| CN104725301A (zh) * | 2013-12-20 | 2015-06-24 | 北京蓝贝望生物医药科技股份有限公司 | 一种1,2-二氢吡啶-2-酮衍生物的制备方法 |
| EA033106B1 (ru) * | 2015-04-21 | 2019-08-30 | Гуйчжоу Бэйлинг Груп Фармасьютикал Ко., Лтд. | Производное пуринил-n-гидроксипиримидинформамида, способы его получения и его применения |
| CN109476710B (zh) * | 2016-07-19 | 2021-11-23 | 国立植物基因组研究所 | 抗真菌病原体的新蛋白质 |
| MX2019004842A (es) * | 2016-11-02 | 2019-06-20 | Curis Inc | Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc. |
| EP3706757A4 (en) * | 2017-11-06 | 2021-08-04 | Cold Spring Harbor Laboratory | PROCESS AND COMPOSITIONS FOR THE MANUFACTURING OF A COPPER-BASED COMPLEX AND THE USE OF IT |
| EP3849554A4 (en) | 2018-09-11 | 2022-06-01 | Curis, Inc. | POLYTHERAPY WITH A PHOSPHOINONOSITIDE 3-KINASE INHIBITOR HAVING A ZINC-BINDING METAL |
| WO2023212574A1 (en) * | 2022-04-26 | 2023-11-02 | Olivia Szu Hsieh Lee Nakaya | Compositions and methods for modulating rhythmic activity of pacemaker cardiomyocytes |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4828991A (en) | 1984-01-31 | 1989-05-09 | Akzo N.V. | Tumor specific monoclonal antibodies |
| US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
| US5502187A (en) | 1992-04-03 | 1996-03-26 | The Upjohn Company | Pharmaceutically active bicyclic-heterocyclic amines |
| US5497763A (en) | 1993-05-21 | 1996-03-12 | Aradigm Corporation | Disposable package for intrapulmonary delivery of aerosolized formulations |
| US5508269A (en) | 1994-10-19 | 1996-04-16 | Pathogenesis Corporation | Aminoglycoside formulation for aerosolization |
| US6777217B1 (en) | 1996-03-26 | 2004-08-17 | President And Fellows Of Harvard College | Histone deacetylases, and uses related thereto |
| US6083922A (en) | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
| US5767068A (en) | 1997-02-13 | 1998-06-16 | Pathogenesis Corporation | Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections |
| CN100345830C (zh) | 2000-04-27 | 2007-10-31 | 安斯泰来制药有限公司 | 稠合杂芳基衍生物 |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| NZ534830A (en) | 2002-03-13 | 2005-08-26 | Janssen Pharmaceutica Nv | Compounds with histone deacetylase HDAC inhibiting activity and oral bioavailability useful for treating proliferative diseases |
| EA007272B1 (ru) | 2002-03-13 | 2006-08-25 | Янссен Фармацевтика Н. В. | Новые ингибиторы гистондеацетилазы |
| ATE398105T1 (de) | 2002-03-13 | 2008-07-15 | Janssen Pharmaceutica Nv | Carbonylamino- derivativate als neue inhibitoren von histone deacetylase |
| MXPA04007776A (es) | 2002-03-13 | 2004-10-15 | Janssen Pharmaceutica Nv | Derivados de sulfonilamino como nuevos inhibidores de histona deacetilasa. |
| WO2004017950A2 (en) | 2002-08-22 | 2004-03-04 | Piramed Limited | Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents |
| KR101074462B1 (ko) | 2003-01-29 | 2011-10-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 티에노피리미딘 화합물 및 그 용도 |
| EP1745022B1 (en) * | 2004-04-05 | 2014-08-13 | Aton Pharma, Inc. | Histone deacetylase inhibitor prodrugs |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| JP4862654B2 (ja) | 2004-10-08 | 2012-01-25 | アステラス製薬株式会社 | 芳香環縮合ピリミジン誘導体 |
| GB0423653D0 (en) | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| NZ599464A (en) | 2005-02-03 | 2014-03-28 | Topotarget Uk Ltd | Combination therapies using hdac inhibitors |
| EP1885710B1 (en) | 2005-05-18 | 2015-08-19 | Janssen Pharmaceutica N.V. | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase |
| CN101374828B (zh) | 2006-01-19 | 2012-09-19 | 詹森药业有限公司 | 作为组蛋白脱乙酰酶抑制剂的杂环烷基衍生物 |
| JP5247470B2 (ja) | 2006-01-19 | 2013-07-24 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ヒストンデアセチラーゼのインヒビターとしてのピリジン及びピリミジン誘導体 |
| EP1979328B1 (en) | 2006-01-19 | 2012-12-26 | Janssen Pharmaceutica N.V. | Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase |
| UA95799C2 (en) | 2006-04-26 | 2011-09-12 | Ф. Хоффманн-Ля Рош Аг | Pharmaceutical compounds |
| EP2041139B1 (en) | 2006-04-26 | 2011-11-09 | F. Hoffmann-La Roche AG | Pharmaceutical compounds |
| CN101511840A (zh) | 2006-04-26 | 2009-08-19 | 吉宁特有限公司 | 磷酸肌醇3-激酶抑制剂化合物及其使用方法 |
| EP2018366A4 (en) | 2006-05-16 | 2010-08-04 | Univ Mcgill | HYBRID MOLECULES HAVING MIXED PROPERTIES OF VITAMIN D RECEPTOR AGONISM AND HISTONE DEACETYLASE INHIBITOR |
| US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
| AU2007296743B2 (en) | 2006-09-11 | 2012-02-16 | Curis, Inc. | Tyrosine kinase inhibitors containing a zinc binding moiety |
| EP2061758A4 (en) | 2006-09-11 | 2011-11-30 | Curis Inc | A ZINC BINDING GROUP CONTAINING SUBSTITUTED 2-INDOLINONE AS PTK INHIBITORS |
| US20080221132A1 (en) | 2006-09-11 | 2008-09-11 | Xiong Cai | Multi-Functional Small Molecules as Anti-Proliferative Agents |
| KR101434164B1 (ko) | 2006-09-11 | 2014-08-26 | 쿠리스 인코퍼레이션 | 아연 결합 부분을 함유한 퀴나졸린 계열 ｅｇｆｒ 억제제 |
| WO2008033745A2 (en) | 2006-09-11 | 2008-03-20 | Curis, Inc. | Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety |
| BRPI0718089A2 (pt) | 2006-10-28 | 2013-11-05 | Methylgene Inc | Composto, uso do composto, composição, e, métodos para inibir histona desacetilase e para tratar uma doença de expansão da poliglutamina |
| JP5284977B2 (ja) * | 2006-12-07 | 2013-09-11 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ホスホイノシチド３−キナーゼ阻害剤化合物及び使用方法 |
| RU2470936C2 (ru) * | 2006-12-07 | 2012-12-27 | Дженентек, Инк. | Соединения-ингибиторы фосфоинозитид 3-киназы и способы применения |
| EP2491923A3 (en) | 2007-02-15 | 2012-12-26 | Novartis AG | Combinations of therapeutic agents for treating cancer |
| WO2008115263A2 (en) | 2007-03-20 | 2008-09-25 | Curis, Inc. | Raf kinase inhibitors containing a zinc binding moiety |
| TW200922590A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | VEGFR inhibitors containing a zinc binding moiety |
| TW200922564A (en) | 2007-09-10 | 2009-06-01 | Curis Inc | CDK inhibitors containing a zinc binding moiety |
| WO2009036020A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Mek inhibitors containing a zinc binding moiety |
| WO2009036057A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Antiproliferative agents containing a zinc binding moiety |
| WO2009036066A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| RU2523890C2 (ru) * | 2007-09-12 | 2014-07-27 | Дженентек, Инк. | Комбинации ингибиторов фосфоинозитид 3-киназы и химиотерапевтических агентов и способы применения |
| WO2009042646A1 (en) | 2007-09-24 | 2009-04-02 | Curis, Inc. | Anti-proliferative agents |
| EP2214675B1 (en) * | 2007-10-25 | 2013-11-20 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| WO2009058895A1 (en) | 2007-10-30 | 2009-05-07 | Syndax Pharmaceuticals, Inc. | Administration of an inhibitor of hdac and an mtor inhibitor |
| WO2009086012A1 (en) | 2007-12-20 | 2009-07-09 | Curis, Inc. | Aurora inhibitors containing a zinc binding moiety |
| EP2311842A3 (en) | 2008-06-24 | 2011-07-13 | Takeda Pharmaceutical Company Limited | PI3K/M TOR inhibitors |
| WO2009155659A1 (en) | 2008-06-27 | 2009-12-30 | The University Of Queensland | Combination therapy |
| US8196911B2 (en) | 2008-10-27 | 2012-06-12 | Honda Motor Co., Ltd. | Adjustable rate subframe mount |
| KR101430424B1 (ko) * | 2009-01-08 | 2014-08-14 | 쿠리스 인코퍼레이션 | 아연 결합 모이어티를 갖는 포스포이노시티드 ３-키나제 억제제 |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| AU2010224125B2 (en) | 2009-03-12 | 2015-05-14 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies |
| CA2776944A1 (en) | 2009-10-12 | 2011-05-12 | F. Hoffmann-La Roche Ag | Combinations of a pi3k inhibitor and a mek inhibitor |
| JP2013525308A (ja) * | 2010-04-16 | 2013-06-20 | キュリス，インコーポレイテッド | Ｋ−ｒａｓ変異を有する癌の治療 |
| RS54903B1 (sr) * | 2011-04-01 | 2016-10-31 | Curis Inc | Inhibitor fosfoinozitid 3 kinaze sa delom koji vezuje cink |
| US20130102595A1 (en) | 2011-04-15 | 2013-04-25 | Curis, Inc. | Treatment of cancers having k-ras mutations |
| WO2013019906A1 (en) | 2011-08-01 | 2013-02-07 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| JP6980980B2 (ja) | 2015-06-25 | 2021-12-15 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 抗ｈｌａ‐ｄｒまたは抗ｔｒｏｐ‐２抗体と微小管阻害剤、ｐａｒｐ阻害剤、ブルトンキナーゼ阻害剤またはホスホイノシチド３‐キナーゼ阻害剤との併用は癌の治療効果を有意に改善する |
| MX2019004842A (es) * | 2016-11-02 | 2019-06-20 | Curis Inc | Terapia de combinación con un inhibidor fosfoinositida 3-cinasa con un resto de unión a cinc. |
-
2012
- 2012-03-30 RS RS20160457A patent/RS54903B1/sr unknown
- 2012-03-30 ES ES16166266T patent/ES2733128T3/es active Active
- 2012-03-30 AU AU2012236367A patent/AU2012236367B2/en active Active
- 2012-03-30 KR KR1020137028748A patent/KR101902325B1/ko active IP Right Grant
- 2012-03-30 CN CN201280026400.9A patent/CN103582483B/zh active Active
- 2012-03-30 MX MX2013011132A patent/MX340577B/es active IP Right Grant
- 2012-03-30 CA CA2830822A patent/CA2830822C/en active Active
- 2012-03-30 LT LTEP16166266.3T patent/LT3111938T/lt unknown
- 2012-03-30 EP EP12764605.7A patent/EP2694075B1/en active Active
- 2012-03-30 US US13/435,062 patent/US8710219B2/en active Active
- 2012-03-30 PT PT16166266T patent/PT3111938T/pt unknown
- 2012-03-30 PL PL12764605.7T patent/PL2694075T3/pl unknown
- 2012-03-30 JP JP2014502821A patent/JP6242331B2/ja active Active
- 2012-03-30 EA EA201301114A patent/EA022434B9/ru unknown
- 2012-03-30 DK DK16166266.3T patent/DK3111938T3/da active
- 2012-03-30 ES ES12764605.7T patent/ES2577982T3/es active Active
- 2012-03-30 KR KR1020187026847A patent/KR20180108848A/ko not_active Application Discontinuation
- 2012-03-30 HU HUE16166266A patent/HUE045041T2/hu unknown
- 2012-03-30 TW TW101111283A patent/TWI571469B/zh active
- 2012-03-30 PE PE2013002160A patent/PE20141382A1/es active IP Right Grant
- 2012-03-30 SI SI201231625T patent/SI3111938T1/sl unknown
- 2012-03-30 SI SI201230597A patent/SI2694075T1/sl unknown
- 2012-03-30 ME MEP-2019-179A patent/ME03523B/me unknown
- 2012-03-30 SG SG10201602569RA patent/SG10201602569RA/en unknown
- 2012-03-30 PL PL16166266T patent/PL3111938T3/pl unknown
- 2012-03-30 CN CN201610034817.XA patent/CN105461736B/zh active Active
- 2012-03-30 EP EP16166266.3A patent/EP3111938B1/en active Active
- 2012-03-30 DK DK12764605.7T patent/DK2694075T3/en active
- 2012-03-30 WO PCT/US2012/031361 patent/WO2012135571A1/en active Application Filing
- 2012-03-30 RS RSP20190842 patent/RS59219B1/sr unknown
- 2012-03-30 SG SG2013070883A patent/SG193563A1/en unknown
- 2012-03-30 ME MEP-2016-116A patent/ME02451B/me unknown
- 2012-03-30 HU HUE12764605A patent/HUE028910T2/en unknown
- 2012-03-30 BR BR112013025340-1A patent/BR112013025340B1/pt active IP Right Grant
- 2012-03-30 PT PT127646057T patent/PT2694075T/pt unknown
-
2013
- 2013-09-19 ZA ZA2013/07082A patent/ZA201307082B/en unknown
- 2013-09-29 IL IL228588A patent/IL228588A/en active IP Right Grant
- 2013-09-30 CL CL2013002823A patent/CL2013002823A1/es unknown
-
2014
- 2014-03-05 US US14/197,769 patent/US9249156B2/en active Active
- 2014-08-11 HK HK14108192.3A patent/HK1194969A1/zh unknown
- 2014-08-21 ZA ZA2014/06167A patent/ZA201406167B/en unknown
-
2015
- 2015-12-28 US US14/979,887 patent/US9657032B2/en active Active
-
2016
- 2016-05-20 HR HRP20160545TT patent/HRP20160545T1/hr unknown
- 2016-06-16 SM SM201600179T patent/SMT201600179B/it unknown
- 2016-07-14 CY CY20161100683T patent/CY1117785T1/el unknown
- 2016-08-08 JP JP2016155625A patent/JP6275784B2/ja active Active
- 2016-10-30 IL IL248597A patent/IL248597B/en active IP Right Grant
-
2017
- 2017-04-25 US US15/496,318 patent/US10111864B2/en active Active
-
2018
- 2018-01-10 JP JP2018001910A patent/JP2018052987A/ja not_active Withdrawn
- 2018-10-03 US US16/150,845 patent/US10543197B2/en active Active
-
2019
- 2019-06-17 HR HRP20191091TT patent/HRP20191091T1/hr unknown
- 2019-07-17 CY CY20191100760T patent/CY1121825T1/el unknown
-
2020
- 2020-01-07 US US16/736,081 patent/US11135205B2/en active Active
-
2021
- 2021-09-09 US US17/470,410 patent/US11654136B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014509653A5 (ja) | ||
| HRP20160545T1 (hr) | Inhibitor fosfoinozitid 3-kinaze sa dijelom koji veže cink | |
| JP2014527042A5 (ja) | ||
| JP2013522326A5 (ja) | ||
| HRP20160135T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za lijeäśenje raka | |
| JP2015536964A5 (ja) | ||
| JP2017537066A5 (ja) | ||
| HRP20171648T1 (hr) | Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze | |
| JP2017525730A5 (ja) | ||
| JP2015508103A5 (ja) | ||
| JP2013525444A5 (ja) | ||
| JP2014193925A5 (ja) | ||
| JP2016503793A5 (ja) | ||
| JP2013526544A5 (ja) | ||
| JP2009242409A5 (ja) | ||
| JP2014504256A5 (ja) | ||
| JP2014502638A5 (ja) | ||
| JP2017514910A5 (ja) | ||
| JP2017519027A5 (ja) | ||
| JP2014518544A5 (ja) | ||
| JP2015516419A5 (ja) | ||
| JP2018510138A5 (ja) | ||
| JP2016530242A5 (ja) | ||
| JP2013544892A5 (ja) | ||
| RU2014117707A (ru) | Способ лечения пролиферативного заболевания |